EC approves expanded use of CAR T-cell therapy Breyanzi for r/r mantle cell lymphoma

FDA approves epcoritamab-bysp for follicular lymphoma indications

FDA approved epcoritamab-bysp with lenalidomide and rituximab for relapsed or refractory follicular lymphoma.

November 21, 2025

EC approves Libtayo as adjuvant treatment of high-risk cutaneous squamous cell carcinoma

The European Commission has approved the PD-1 inhibitor Libtayo (cemiplimab) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.

November 21, 2025

Vol.51 No.43

Drugs & Targets

EC approves Keytruda for subcutaneous use

The European Commission has approved a subcutaneous, or under the skin, route of administration and a new pharmaceutical form (solution for injection) of Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy.

November 21, 2025

Vol.51 No.43

Drugs & Targets

EC approves Keytruda combination for a head-and-neck indication

The European Commission approved Keytruda (pembrolizumab), an anti-PD-1 therapy, as a monotherapy for the treatment of resectable locally advanced head-and-neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumors express PD-L1 with a Combined Positive Score ≥1.

October 31, 2025

Vol.51 No.40

Clinical Roundup

Next-gen CAR T cells show promise at treating solid tumors, USC study shows

Using cell cultures and animal models, researchers from the USC Norris Comprehensive Cancer Center at Keck School of Medicine of USC showed that next-generation CAR T cells can safely and effectively shrink solid tumors.

October 10, 2025

Vol.51 No.37

The evolution of cellular immunotherapy: From transplant to CAR T cells

Nearly five decades ago, I joined City of Hope’s nascent bone marrow transplant (BMT) program, which focused on improving outcomes for patients with advanced leukemia.

October 03, 2025

Vol.51 No.36

By Stephen J. Forman